CD16+monocytes in breast cancer patients: expanded by monocyte chemoattractant protein-1 and may be useful for early diagnosis
CD16+monocytes in breast cancer patients: expanded by monocyte chemoattractant protein-1 and may be useful for early diagnosis
复制标题
DOI：
10.1111/j.1365-2249.2011.04321.x
复制
发表时间：
2011-04-01
影响因子：
4.6
通讯作者：
Qu, X.
中科院分区：
文献类型：
--
作者：
Feng, A-L.;Zhu, J-K.;Qu, X.
P>人外周血单核细胞是一个异质群体，包括 CD14+CD16-“经典”单核细胞和 CD14+CD16+“促炎”单核细胞。 CD16+ 单核细胞在各种炎症条件下都会扩增。然而，人们对乳腺癌患者的 CD14+CD16+ 单核细胞知之甚少。我们使用流式细胞术检测了 96 名乳腺癌患者和 54 名对照受试者的 CD14+CD16+ 单核细胞。采用受试者工作特征（ROC）曲线分析确定CD14+CD16+单核细胞作为乳腺癌诊断指标的可行性。我们发现乳腺癌患者中 CD14+CD16+ 单核细胞的频率显着高于对照组（16 中心点 96% 对比 10 中心点 84%，P < 0 中心点 0001）。 CD14+CD16+单核细胞的ROC曲线下面积为0中心点805[95%置信区间(95%CI)：0中心点714-0中心点877，P=0中心点0001]。此外，CD16+单核细胞的水平与肿瘤大小和病理分期显着负相关。在体外，我们发现，当纯化的 CD14+ 单核细胞暴露于密歇根癌症基金会 (MCF)-7 细胞条件培养基 (MCF-CM) 或单独暴露于单核细胞趋化蛋白 1 (MCP-1) 时，CD14+CD16+ 单核细胞显着扩增。针对MCP-1的中和抗体抑制MCF-CM对CD14+CD16+单核细胞的扩增。总的来说，我们的研究结果表明 MCP-1 可以扩增乳腺癌患者的 CD14+CD16+ 单核细胞。此外，CD14+CD16+单核细胞可能是乳腺癌早期诊断的有用指标。
P>Human peripheral blood monocytes are a heterogeneous population, including CD14+CD16- 'classical' monocytes and CD14+CD16+ 'proinflammatory' monocytes. CD16+ monocytes are expanded in various inflammatory conditions. However, little is known about the CD14+CD16+ monocytes in patients with breast cancer. We detected CD14+CD16+ monocytes in 96 patients with breast cancer and 54 control subjects using flow cytometry. Receiver-operating characteristic (ROC) curve analysis was used to determine the feasibility of CD14+CD16+ monocytes as an indicator for diagnosis of breast cancer. We found that the frequency of CD14+CD16+ monocytes showed a significantly greater increase in breast cancer patients than in controls (16 center dot 96% versus 10 center dot 84%, P < 0 center dot 0001). The area under the ROC curve for CD14+CD16+ monocytes was 0 center dot 805 [95% confidence interval (95% CI): 0 center dot 714-0 center dot 877, P = 0 center dot 0001]. Furthermore, the levels of CD16+ monocytes were significantly negatively associated with the tumour size and pathological staging. In vitro, we showed that CD14+CD16+ monocytes were expanded significantly when the purified CD14+ monocytes were exposed to Michigan Cancer Foundation (MCF)-7 cells-conditioned medium (MCF-CM) or, separately, to monocyte chemotactic protein 1 (MCP-1). Neutralizing antibodies against MCP-1 inhibited the expansion of CD14+CD16+ monocytes by MCF-CM. Collectively, our findings indicated that MCP-1 can expand CD14+CD16+ monocytes in patients with breast cancer. Furthermore, the CD14+CD16+ monocyte may be a useful indicator in early diagnosis of breast cancer.